NCT03526978 is a Phase 3 clinical trial of Investigational sIPV in Poliomyelitis, sponsored by Sinovac Biotech Co., Ltd.

Who is sponsoring NCT03526978?

NCT03526978 is sponsored by Sinovac Biotech Co., Ltd.

What drugs are being tested in NCT03526978?

Interventions in NCT03526978: Investigational sIPV, Control IPV.

What condition does NCT03526978 study?

NCT03526978 studies Poliomyelitis.

Is NCT03526978 still recruiting?

NCT03526978 is currently completed. Last updated 25 January 2019.

Last reviewed 2019-01-25 · How we verify

NCT03526978

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Completed Phase 3 Last updated 25 January 2019

What this trial tests

Phase 3 trial testing Investigational sIPV in Poliomyelitis in 1,200 participants. Completed in 18 April 2018.

Timeline

8 August 2017

Primary endpoint
18 October 2017

18 April 2018

Quick facts

Lead sponsor	Sinovac Biotech Co., Ltd
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	1,200
Start date	8 August 2017
Primary completion	18 October 2017
Estimated completion	18 April 2018
Sites	1 location across China

Drugs / interventions tested

Investigational sIPV — full drug profile →
Control IPV — full drug profile →

Conditions studied

Poliomyelitis — all drugs for Poliomyelitis →

Sponsor

Sinovac Biotech Co., Ltd — full company profile →

Who can join

Adults 60 Days to 90 Days, any sex, with Poliomyelitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
Hu Y, Wang J, Zeng G, Chu K, et al · · 2019 · cited 29× · PMID 30958543 · DOI 10.1093/infdis/jiy736
Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants.
Gao S, Wei M, Chu K, Li J, et al · · 2022 · cited 3× · PMID 35394898 · DOI 10.1080/21645515.2022.2050106
Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination.
Kai C, Yurong L, Sheng L, Yongmei S, et al · · 2025 · PMID 40266111 · DOI 10.3390/vaccines13030253

Verify or expand the search:

Other trials of Investigational sIPV

Trials testing the same drug.

NCT04989231 — An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses · completed

Other recruiting trials for Poliomyelitis

Currently open trials in the same condition.

NCT07457060 — Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine · Phase 4 · recruiting
NCT06895486 — Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation · Phase 2 · recruiting
NCT07354269 — Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations · Phase 4 · recruiting
NCT06137664 — Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines · Phase 1, PHASE2 · recruiting
NCT05644184 — Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh · Phase 2 · recruiting

Other Sinovac Biotech Co., Ltd trials

Trials by the same sponsor.

NCT07418229 — Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine · Phase 1 · not yet recruiting
NCT07416110 — Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine · Phase 3 · not yet recruiting
NCT07055295 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
NCT07055893 — Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen · Phase 3 · not yet recruiting
NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03526978 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinovac Biotech Co., Ltd
Last refreshed: 25 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526978.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing